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Lycopene in fruits and vegetables occurs mostly (80–97 %) in the all-E configuration, whereas a considerable proportion of lycopene in the human
body is present as Z-isomers. The Z-isomers offer potentially better health benefits and show improved antioxidant activity in vitro when compared
with the all-E-isomer. The absorption of dietary lycopene is a complex process involving transfer of the carotenoid from the food matrix into
micelles, uptake by enterocytes, packaging into chylomicrons and finally secretion into plasma. Isomerisation could take place at any of these
individual steps. By exploiting in vitro and in vivo models, we traced lycopene isomerisation during absorption using various methods to
mimic gastric and duodenal conditions, incorporation into mixed micelles, absorption and metabolism by various Caco-2 cell clones, and
performed a postprandial study in human subjects to identify the profile of lycopene isomers in plasma chylomicrons. We demonstrate that
all-E-lycopene remains unchanged during its passage in the gastrointestinal tract, including its incorporation into mixed micelles. The key site
of lycopene isomerisation is inside the intestinal cells resulting in 29 % of lycopene as Z-isomers. Lycopene isomerisation in the various
Caco-2 cell clones is consistent with that observed in human chylomicrons formed in a postprandial state. There is no selection in the release
of lycopene isomers from enterocytes. Although there is a huge inter-individual variability of total lycopene absorption reported both in
in vitro intestinal cell lines as well as in human chylomicrons, the lycopene isomer profile is quite similar.
Z-lycopene: Intestinal absorption: Isomerisation: Bioavailability: Carotenoids
Lycopene is an acyclic C40 non-polar carotenoid, present
in several dietary sources such as tomato, watermelon,
guava and apricot(1). Although lycopene is not a provitamin
A, studies have shown multiple biological activities including
decreased risk of prostate cancer(2), inhibition of cell prolifer-
ation, migration and invasion in breast, endometrial and liver
carcinoma cells(3 – 8), and prevention of mutagenesis and
chromosome instability(9,10). In addition, a variety of epide-
miological trials indicated that high intakes of lycopene-
containing foods (primarily tomato products) or blood
lycopene concentrations are associated with decreased risk
of CVD and prostate cancer(11 – 15).
Lycopene has eleven conjugated double bonds and each of
them could be either in an E or Z configuration. All-E-lycopene
is the predominant isomer in plants, representing about
80–97 % of total lycopene in tomatoes and related products(16).
In human body fluids and tissues such as plasma, breast milk,
prostate, testis and skin, 25–70 % of lycopene is found in
various Z forms(17 – 24). The high concentrations of Z-isomers
in vivo triggered the hypothesis that they may be more bioavail-
able and/or have a different specific bioactivity. In terms of
bioefficacy, Shi & Le Maguer(16) indicated that the biological
potency of Z-lycopene isomers is different from that of the
all-E form. Bo¨hm et al. (25) found that some Z-isomers had
a stronger in vitro antioxidant activity than the all-E form.
For these reasons, Z-lycopene isomers are regarded as offering
potentially better health benefits than the all-E-isomer.
Although Z-lycopene is the main component in human
plasma and tissues, it is still not known if Z-isomers are
absorbed preferentially from the food and/or if isomerisation
occurs in humans. According to Tyssandier et al. (26), lycopene
appears in plasma chylomicrons mostly as all-E-lycopene
after consumption of a tomato-rich meal. In contrast, Gustin
et al. (27) and Unlu et al. (28) reported that about 40 % of
lycopene is present in chylomicrons as Z-lycopene isomers,
indicating that lycopene isomerisation could take place
during absorption. When a tomato-based meal rich in the
all-E-isomer is consumed daily over a few weeks, plasma
lycopene concentration increases, where 60 % is as Z-lycopene
isomers and 40 % is as all-E-lycopene(29,30).
In the present study, we investigated the isomerisation of
lycopene during the absorption process. This evaluation has
been performed at different stages of absorption: under con-
ditions in the gastrointestinal tract using simple in vitro
models such as gastric and duodenal juices, incorporation
into mixed micelles and using the more sophisticated gastro-
intestinal model (TIM-1), under conditions found in enterocytes
using Caco-2 cells as a model of human intestinal epithelium,
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and in vivo, in chylomicrons released during the postprandial
phase in humans.
Materials and methods
Tomato products
Tomato paste, used for the TIM-1 model and for the human
clinical trial, was obtained from Thomy (Vevey, Switzerland).
It contained 0·0751 g lycopene per 100 g. Tomato oleoresin,
used for the in vitro experiments, was purchased from
Indena (Milan, Italy). It was prepared by ethyl acetate extrac-
tion of tomatoes and its lycopene content was 8·8 g per 100 g.
Both tomato extracts had an identical profile of lycopene iso-
mers consisting of about 94 % all-E- and 5 % 5-Z-isomers.
In addition to lycopene, these tomato extracts contained
phytoene, phytofluene and b-carotene, but in lower amounts.
Typically, in tomato paste lycopene, phytoene, phytofluene
and b-carotene contributed 79, 12, 6 and 3 % of total caroten-
oids, respectively.
Gastric and duodenal juices
Gastric juice (100 ml) was prepared using 0·3 g pepsin and
0·5 g NaCl dissolved in 80 ml distilled water; pH was adjusted
with 1 M-HCl. The solution was transferred into a volumetric
flask and the volume adjusted to 100 ml. Before every exper-
iment, gastric juice was mixed with sodium chloride (0·5 %)
with a ratio 20:6 (v/v). Final pH was in the range of 2–4.
Duodenal juice was prepared by mixing a water solution
of 4·9 % porcine bile with a solution of 2·42 % pancreatin
(in water) and sodium phosphate buffer of pH 7·0 (39 mM-
NaH2PO4 and 62·5 mM-Na2HPO4H2O) with a ratio of 1:1:7
(by vol.). All the chemicals and digestive enzymes used to
prepare the gastric and duodenal juices were from Sigma
(Basel, Switzerland).
For every test on gastric or duodenal juice, 2 mg tomato oleor-
esin were weighed into a dark Pyrex tube and incubated with
0·8 g groundnut oil under agitation at room temperature for
90 min. After this period, 4 ml gastric juice or 4 ml duodenal
juice or a combination of 3 ml of each were added to the tube
and incubated at 378C. Samples were collected after 15 min,
30 min, 1 h and 2 h for the gastric juice and after 30 min, 1 h
and 2 h for the duodenal juice and stored at2808C until analysis
of their total lycopene content and their lycopene isomer profile.
Mixed micelles preparation
Artificial mixed micelles were used to screen for isomerisation
within the gastrointestinal tract and also to deliver lycopene to
Caco-2 cells. Tomato oleoresin, as the lycopene source, was
dissolved in dichloromethane. The preparation of mixed
micelles was performed according to Sugawara et al. (31).
Dynamic gastrointestinal model
The dynamic gastrointestinal model (TIM-1) was from TNO
(Wageningen, The Netherlands) as described in detail by
Minekus et al. (32). The digestive enzymes used with this
model are pepsin, porcine bile, trypsin and (-amylase
from Sigma (Basel, Switzerland), Pancrex V powder from
Paines & Byrne (Staines, Middlesex, UK) and lipase from
Amano (Chipping Norton, Oxon, UK). Tomato paste (5 g)
present in a 125 g portion of the standard meal was tested in
duplicate. The standard meal consisted of semolina (70 g)
cooked in 200 ml hot water, white bread (40 g), egg whites
(60 g), groundnut oil (40 g), natural yoghurt (125 g), sugar
(5 g) and water (330 g) and was of the same composition as
the one used in the human intervention study.
Tissue culture
Caco-2 cell monolayers are a model of the human intestinal
epithelium. Caco-2 cells spontaneously differentiate into
polarised absorptive cell monolayers and, after differentiation,
display morphological and biochemical characteristics similar
to human enterocytes. This model gives reproducible values
that closely correlate with in vivo data and has been used to
study the molecular mechanisms involved in the absorption
of carotenoids(33 – 35). For the present study we used three
different Caco-2 cell clones: Caco-2 SM, a generous gift of
Dr Shubha Murthy (University of Iowa, USA), Caco-2 and
Caco-2 HTB37 which were obtained from the America Type
Culture Collection (ATCC; Rockville, MD, USA). For main-
tenance, Caco-2 and Caco-2 HTB37 cells were seeded at a
density of 40 £ 103 cells/cm2, and cultured in a humidified
incubator at 10 % CO2 and 378C in Dulbecco’s modified
Eagle’s medium containing 4·5 g glucose/l, 20 % fetal
bovine serum, 1 % non-essential amino acids, gentamicin
(150mg/ml), fungizon (1mg/ml), penicillin (100 U/ml) and
streptomycin (100 mg/ml). Caco-2 SM cells were seeded at
a density of 6·7 £ 103 cells/cm2 and cultured in a humidified
incubator at 5 % CO2 and 378C in Dulbecco’s modified
Eagle’s medium containing 4·5 g glucose/l, 10 % fetal
bovine serum, gentamicin (150mg/ml), penicillin (100 U/ml),
streptomycin (100 mg/ml) and 2 mM-L-glutamine. The
medium was changed every 2 d. In order to obtain differen-
tiated monolayers, Caco-2 and Caco-2 HTB37 cells were
seeded at a density of 1 £ 106 cells/well and cultured for
21 d. Caco-2 SM cells were seeded at a density of 1·5 £ 105
cells/well and cultured for 14 d.
Cellular lycopene uptake
Medium (2 ml) containing lycopene-rich mixed micelles (2mM
of total lycopene) was incubated with the different Caco-2 cell
clones for periods of 2 or 6 h. After the incubation, the super-
natant fraction of the wells was collected on dry ice and stored
at 2808C pending analysis of total lycopene content as well as
lycopene isomer profile. The cell monolayers were washed
twice with PBS and cells were lysed with 5 % sodium dodecyl
sulfate. The lysate was also collected on dry ice and stored at
2808C pending analysis of the total lycopene content and
isomer profile.
Human intervention study
Subjects. There were thirty healthy men enrolled in the study.
A total of twenty-seven subjects, aged 24 (SEM 1) years,
completed the study. Their mean starting body weight was
70 (SEM 1) kg and BMI was 22·5 (SEM 0·3) kg/m2. The present
study was conducted according to the guidelines laid down
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in the Declaration of Helsinki and all procedures involving
human subjects were approved by the ethical committee of
Marseille (Marseille, France). All subjects received informa-
tion on the background and design of the study and gave
written informed consent before participation. They were free
to withdraw from the study at any time.
Study design. Subjects were asked to refrain for 48 h
before the postprandial test from eating tomato (fresh or
sauce including ketchup and harissa), pizza, ratatouille,
lasagna, pasta including tomato sauce, watermelon, pink
grapefruits and guava. In addition to this dietary restriction,
the subjects ate a standard meal the evening before the post-
prandial test consisting of green vegetables, a source of cereals
(paste, bread or rice), lean meat or fish, one low-fat natural
yoghurt, one fruit and one mineral water. They should have
consumed this dinner in the evening between 19.00 and
20.00 hours. These recommendations were checked by the
investigator on the postprandial test day. After an overnight
fast, each subject consumed a standard meal (as previously
described in the TIM section). This meal was consumed
within 30 min. No other food was allowed over the following
6 h, but the subjects were allowed to drink bottled water.
Blood samples were drawn before administration of the stan-
dard meal as well as at 2, 3, 4, 5 and 6 h post-absorption and
introduced into evacuated tubes containing K-EDTA. The
tubes were immediately placed into an ice-water-bath.
TAG-rich lipoprotein isolation. On the test day, plasma
(6 ml) was overlaid with 0·9 % NaCl solution and centri-
fuged for 28 min at 32 000 rpm at 108C in an SW41Ti rotor
(Beckman, Fullerton, CA, USA) in an L7 ultracentrifuge
(Beckman). The upper phase containing TAG-rich lipo-
proteins (TRL), i.e. mainly chylomicrons with low amounts
of VLDL, was collected. Immediately after recovery, TRL
were divided into samples and immediately stored at
2808C. Total lycopene content and lycopene isomer profile
were determined within 10 d.
Lycopene determination
Total lycopene content and the profile of lycopene isomers
were determined according to the method described previously
by Schierle et al. (21) for lycopene products (Fig. 1) and
in vitro models, and according to the method of Ferruzzi
et al. (36) for TRL. The main lycopene isomers identified are
5-Z-, 9-Z-, 13-Z- and all-E-lycopene. Minor compounds
(shown with an asterisk in Fig. 1) consisted of other Z-lyco-
pene isomers. They were characterised as Z-lycopene with
liquid chromatography (LC)–MS/MS using an Applied
Biosystems APIC 4000 LC–MS/MS (Foster City, CA,
USA): isocratic flow 1 ml/min; declustering potential, 130 V;
60 psi (414 kPa) N2; capillary voltage 22 V; vaporiser tempera-
ture, 4008C; corona needle 5mA; the fragmentation conditions
used were as described by dos Anjos Ferreira et al. (22). The
peak areas of unidentified Z-lycopene isomers were summed
and reported as x-Z-lycopene (Table 1).
Expression of the results
Total lycopene is the sum of all lycopene isomers, i.e. all-E-
and Z-isomers. Results of in vitro experiments are expressed
as mean values and standard deviations. Results of TRL
from the human intervention study are expressed as mean
values with their standard errors.
Results
A simplified scheme of the absorption process of carotenoids
in humans is depicted in Fig. 2. We used several models
(in vitro and in vivo) to determine at which stage lycopene
can undergo isomerisation: (1) within the lumen of the
gastrointestinal tract; (2) incorporation into mixed micelles;
(3) within the small intestine using three Caco-2 cell clones
and (4) during release from enterocytes in vivo into human
blood plasma (chylomicrons or TRL).
Lycopene isomerisation within the gastrointestinal tract
Lycopene in either tomato paste or tomato oleoresin consists
of 94 % all-E- and 5 % 5-Z-isomers.
Step 1 in Fig. 2. We assessed lycopene isomerisation
within the gastrointestinal tract using various in vitro
models. Lycopene did not undergo Z isomerisation in the
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Fig. 1. Representative HPLC chromatogram of lycopene isomers. * Presence of other Z-lycopene isomers as confirmed by liquid chromatography–MS/MS.
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presence of gastric juice at pH values between 2 and 4, nor in
the presence of duodenal juice at pH 7 and also not when incu-
bated sequentially in both conditions (data not shown).
Step 2 in Fig. 2. Incorporation of lycopene into mixed
micelles did not induce any degradation of lycopene (data not
shown), or any change of lycopene isomer profile (Table 1).
Steps 1 and 2 in Fig. 2. In the gastrointestinal model,
TIM-1, mimicking both conditions in the stomach and the
small intestine, the lycopene isomer profile of the tomato pro-
duct remained unchanged, confirming that lycopene isomerisa-
tion did not take place in the gastrointestinal lumen (Table 1).
Lycopene isomerisation within the intestine
Step 3 in Fig. 2. The next step in the lycopene absorption
process is the transfer from the mixed micelles into human
enterocytes. As a model for human enterocytes, differentiated
Caco-2 cells (Caco-2, Caco-2 SM and Caco-2 HTB37) were
incubated with mixed micelles containing lycopene (2mM).
The content as well as the isomer profile of lycopene present
in mixed micelles were stable for at least 6 h under cell-culture
conditions in the absence of cells.
Cells efficiently took up lycopene from mixed micelles in a
time-dependent manner leading to a 13 % transfer of lycopene
from the mixed micelles into Caco-2 or Caco-2 SM cells at
the end of the 6 h incubation, while this transfer was about
four times lower (3 %) for the Caco-2 HTB37 clone. The
intracellular lycopene isomer profile was similar in the three
cell clones and consisted of a significantly higher proportion
of Z-isomers than in the starting material: 5-Z (12·1 (SD
1·6) % total lycopene) . 13-Z (5·6 (SD 1·2) % total
lycopene) . 9-Z (2·9 (SD 0·5) % total lycopene) . x-Z (2·7
(SD 4·7) % total lycopene). The lycopene isomer profile in
the cells was similar after 2 and 6 h incubation (data not
shown), even though the total lycopene content was lower
after 2 h. The absence of Z-lycopene isomers in the incubation
medium indicates that lycopene isomerisation took place
within the cells.
Table 1. Lycopene isomer profiles measured in tomato paste and tomato oleoresin, in gastrointestinal milieu (TIM-1), in mixed
micelles, in Caco-2 cells as well as in human TAG-rich lipoproteins (TRL) secreted postprandially*
(Mean values and standard deviations or standard errors)
Tomato paste
and tomato
oleoresin (n 4)
Gastrointestinal
milieu (TIM-1)
(n 2)
Mixed micelles
(n 6)
Caco-2 cells
(n 4 for the three
clones in total)
Human TRL
(n 27)
Isomer Mean SD Mean SD Mean SD Mean SD Mean SEM
All-E 93·9 1·8 90·8 0·6 94·3 1·7 76·7 6·9 72·1 1·4
5-Z 5·0 1·3 4·7 0·1 4·7 1·1 12·1 1·6 10·8 0·7
9-Z 0·4 0·3 0·4 0·0 0·4 0·3 2·9 0·5 1·3 0·1
13-Z 0·5 0·6 3·4 0·4 0·5 0·5 5·6 1·2 7·2 0·2
x-Z† 0·2 0·4 0·5 0·1 0·2 0·3 2·7 4·7 9·3 1·3
*Results are expressed as percentage of total lycopene.
† x-Z ¼ sum of unidentified Z-lycopene isomers.
Chylomicron
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Fig. 2. Simplified scheme of the absorption of lycopene in human subjects. The in vitro and in vivo model systems mimicking different stages of lycopene digestion
and absorption that were used during the work are indicated as 1–4.
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Lycopene isomerisation during absorption in humans
Step 1 to step 4 in Fig. 2. We performed a postprandial test
in healthy males to allow characterisation of the lycopene
appearing in intestinal secreted lipoproteins, i.e. chylomicrons.
Subjects consumed a standard meal containing lycopene pre-
sent in tomato paste, i.e. providing mainly all-E-lycopene
(Table 1). This standard meal contained 40 g groundnut oil
to ensure that subjects would secrete chylomicrons into the
blood circulation. Consumption of the standard meal led to a
marked production of chylomicron particles in TRL as charac-
terised by the increase of plasma TAG concentration
(Fig. 3(a)). Lycopene was efficiently absorbed and secreted
in chylomicrons as shown by the rise of TRL-lycopene
concentration (Fig. 3(b)). The profile of lycopene isomers
appearing in TRL consisted of 29 % of Z-lycopene isomers
with the proportion decreasing in the following order: 5-Z
(10·8 (SD 0·7) %); x-Z (9·3 (SD 1·3) %); 13-Z (7·2 (SD 0·2)
%); 9-Z (1·3 (SD 0·1) %). This profile of Z-lycopene isomers
was similar between 2 and 6 h post-absorption. In contrast
to the 23-fold inter-individual variation observed for total
lycopene bioavailability, the proportion of Z-lycopene isomers
in TRL only showed an inter-subject variation of 4 (Fig. 4).
This indicates that ‘low’ and ‘high’ lycopene absorbers(19 – 21)
exhibit quite similar ability to isomerise lycopene.
Discussion
The absorption of lycopene requires lycopene partitioning
into bile salt micelles during small intestine digestion,
uptake across the brush-border membrane of enterocytes and
incorporation into chylomicron particles for secretion into
lymph (Fig. 2).
Lycopene isomerisation did not take place in the gastrointes-
tinal lumen either in the stomach, in the duodenum, or during
transfer into mixed micelles, as assessed with various in vitro
models. In contrast, all-E-lycopene was isomerised into various
Z-lycopene isomers when in contact with various clones of
Caco-2 cells. Lycopene absorption with a meal led to the
secretion of chylomicrons present in TRL containing about
29 % of lycopene as Z-lycopene isomers. The proportion of
individual lycopene isomers in Caco-2 cell monolayers, and
in human TRL, was quite consistent, and decreased in the
following order: 5-Z . 13-Z ¼ x-Z . 9-Z. The presence of
9-Z-, 13-Z- and x-Z-isomers indicates lycopene isomerisation
rather than preferential uptake of Z-lycopene, since these lyco-
pene isomers were absent in the test lycopene preparations
which contained about 94 % all-E- and about 5 % 5-Z-lycopene.
However, this does not exclude a preferential uptake of 5-Z-
lycopene by cells, since its proportion was higher in the Caco-2
cell monolayers and TRL than in the lycopene preparation.
Given that isomerisation of all-E-lycopene into Z-isomers is
promoted by contact with acids(37), our first goal was to assess
whether there was any isomerisation of lycopene in the acidic
environment of the stomach and the small intestine. Our find-
ing showing an absence of lycopene isomerisation in the
stomach is in agreement with results obtained in vitro (38)
and in healthy subjects(26). However, they disagree with
in vitro results showing an isomerisation of lycopene that
has been reported in vitro in a ‘gastric milieu’ set at pH
1·6(26,39). This discrepancy might be due to the use of a low
pH in this in vitro model, which mimics the stomach pH in
the fasting stage only. Indeed, the stomach pH, which is
about 1·8 in the fasting state, sharply increases to 5·4–6·2
after intake of a meal, and then continuously decreases to
reach 1·8–2·9 after 3 h digestion. The duodenal pH, which is
about 5 in the fasting state, increases to pH 6·1–6·6 after
intake of a meal and remains constant during digestion.
In the present results, we did not observe isomerisation of
lycopene in the in vitro model mimicking this duodenal con-
dition. In the gastrointestinal lumen, the final step before
absorption is the transfer of lycopene into mixed micelles.
The isomer profile of lycopene in the mixed micelles was
similar to the one of the tomato product, which indicates no
lycopene isomerisation, but also no preferential transfer of
Z-lycopene (in our particular case, 5-Z-lycopene). This is in
disagreement with results of Boileau et al. (40) showing a
higher incorporation of Z-lycopene into mixed micelles than
the all-E counterpart. Using the more sophisticated TIM-1
model, which is an in vitro model that allows the closest simu-
lation of in vivo dynamic physiological processes occurring in
the lumen of the stomach currently available, we confirm that
lycopene does not undergo isomerisation in the gastrointesti-
nal tract. These results are in agreement with those recently
reported by Blanquet-Diot et al. (41). Although the main para-
meters of digestion, such as pH, body temperature, peristaltic
mixing and transport, gastric, biliary and pancreatic secretions
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and passive absorption of small molecules and water are
reproduced, the actual limitations of the TIM-1 model reside
in the absence of a cellular system and a feedback mechanism.
To mimic enterocyte transport and metabolism, we used
three clones of Caco-2 cells. Cell culture condition did not
affect either lycopene content or isomer profile. Lycopene
uptake by either Caco-2 or Caco-2 SM was similar, but
markedly lower by Caco-2 HTB37 cells. However, lycopene
isomerised in all these three cell clones and the profile of
lycopene isomers were similar. The results in Caco-2 cells
matched in vivo results. Lycopene appearing in chylomicrons
(TRL) and in Caco-2 cells consisted of 29 and 24 %, respect-
ively, as a mixture of Z-lycopene isomers. This is in agree-
ment with results described by Gustin et al. (27) and Unlu
et al. (28). In contrast, Tyssandier et al. (26) did not detect
Z-lycopene isomers in chylomicrons isolated from plasma
from most individuals. Although a large inter-individual vari-
ation of lycopene bioavailability is in agreement with data
reported by several authors(42 – 44) and is characteristic of the
presence of low and high absorbers in the population, a low
inter-individual variation of the proportion of Z- to E-lycopene
is noteworthy. These results indicate that whatever the lyco-
pene absorption efficiency, lycopene isomerisation is quite
similar and suggest that the factors participating in lycopene
absorption are different from those involved in lycopene
isomerisation.
In most human tissues, more than 50 % of the lycopene is
a mixture of Z-isomers(23,28,44,45). The major Z-isomers in
plasma were, in decreasing order of abundance: 5-Z . 13-Z
. 9-Z. In humans, the Z-lycopene concentration is high in
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Fig. 4. Inter-individual variation: total lycopene concentration (a) and percentage of all-Z-lycopene isomers (b) in TAG-rich lipoproteins (TRL) of each individual
subject having consumed a standard meal containing lycopene (n 27). Results are expressed in nM for total lycopene and as percentage of total lycopene for the
all-Z-lycopene isomers. The all-Z-lycopene isomers consist of the sum of 5-Z-, 9-Z-, 13-Z- and unidentified Z-lycopene isomers. AUC, area under the curve.
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the liver, adrenal glands, testes, skin and prostate(18,46,47).
The 29 % Z-lycopene in human chylomicrons present in
TRL suggests that, in the human body, additional mechanisms
are involved which increase markedly the proportion of
Z-lycopene by processes such as isomerisation, preferential
uptake or reduced catabolism of the Z-lycopene isomers.
The high proportion of Z-lycopene isomers in human tissues
could conceivably be a conversion to a more biologically
effective form. It is not feasible to compare the efficacy of
Z- and E-lycopene in vivo, owing to the metabolic conversion
of one form to another. However, Bo¨hm et al. (25) demon-
strated that Z-lycopene isomers exhibit higher antioxidant
capacity than their all-E counterpart in vitro. Thus it is tempt-
ing to speculate that the E- to Z-lycopene conversion in vivo
is a metabolic activation of this carotenoid.
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